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The human severe acute respiratory syndrome coronavirus (SARS-CoV) is a highly infectious agent that requires specific biosafety level 3 laboratory practices. The present study investigated the possibility to pseudotype an HIV-based vector with the SARS-CoV spike envelope protein for facilitating the characterization of this envelope in a safer and less restrictive environment. Spike-pseudotyped HIV vector (spike-HIV) could be produced and concentrated to generate vector stocks containing in the range of 10^5^ transducing units (TU) per ml as determined by limiting dilution on 293T and VeroE6 cells. Spike-HIV vector was compared to wild-type SARS-CoV for transduction/infection of different tissues and the ability to detect neutralizing antibody (NAB) to SARS-CoV from immune serum. Results show that Spike-HIV vector encoding for LacZ (Spike-HIV-LacZ) was slightly more sensitive at detecting the presence of NAB from SARS-CoV immune sera than wild-type SARS-CoV. In addition, both Spike-HIV-LacZ and SARS-CoV could transduce/infect culture of primary human cells such as dendritic and airway epithelial cells. Localization of Spike-HIV-LacZ and SARS-CoV following in vivo administration in the airway of mice will be presented. Overall, results indicate that it is possible to pseudotype HIV vector with the SARS-CoV spike glycoprotein for studying B cell response directed against the virus as well as its natural viral tropism. Spike-HIV vector should facilitate the characterization of SARS-CoV tropism to a high number of different cell types *in vitro* and *in vivo*. This could help selecting an optimal animal model and provide a better understanding of the pathogenesis associated with SARS-CoV infection.
